ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
批准号:
6889834
负责人:
LISA A FORTIER
金额:
$12.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-15 至 2006-01-31
关键词:
biological signal transductioncell differentiationcell growth regulationchondrocytesgene expressionguanine nucleotide binding proteinhorsesimmunofluorescence techniqueinsulinlike growth factorinterleukin 1microinjectionsosteoarthritisprotein localizationprotein structure functiontumor necrosis factor alphavaccinia virus
中文摘要
MCSDA可以让我作为一名兽医和博士,扩展我的软骨生物学知识,并进一步了解软骨细胞代谢,以寻找预防或治疗骨关节炎的方法。我选择的导师在细胞内信号方面是国际公认的,并且在培养科学家成为独立研究人员方面有着良好的记录。本研究概述了rho亚家族gtp结合蛋白信号在软骨细胞分化中的作用。RhoA结合蛋白(Cdc42, Rac, RhoA)调节肌动蛋白细胞骨架结构,并参与诱导软骨细胞去分化和软骨降解的白细胞介素-1 (IL-1)信号传导。胰岛素样生长因子- i (IGF-I)促进分化软骨细胞的表型表达,并可减轻IL-1和肿瘤坏死因子(TNF)的降解作用。因此,维持分化的软骨细胞表型和预防骨关节炎的关键可能在于IGF- i通过Cdc42、Rac或RhoA调节的细胞因子信号。本研究的主要目的是确定IGF-I在调节IL-1/ tnf诱导的去分化中所起的作用。在第一阶段的培训中,我将获得生化和基于分子的方法来研究软骨细胞中rho蛋白信号通路的经验。目的1将研究igf -1、IL-1和TNF如何影响Cdc42、Rac和RhoA的激活和定位。目的2将采用显微注射方法来确定突变(组成活性或非活性)rho蛋白是否可以促进形态去分化。Aim 3将研究痘苗病毒表达、突变(组成活性或非活性)rho蛋白刺激表型去分化的能力。在II期,我将开始一个独立的研究项目,这将进一步扩展我对软骨细胞中rho蛋白信号传导的认识,重点是鉴定参与软骨细胞分化的rho靶蛋白。我将重点介绍RhoA的特异性靶点Rho激酶和Cdc42和Rac的特异性靶点PAK-2 (p21活化激酶)。牛痘病毒系统将用于表达Rho激酶和PAK-2的组成型活性或激酶死亡突变体,以确定这些激酶对软骨细胞分化的影响。期望这些研究将为软骨细胞分化的调控提供重要的见解,而最终目标是利用所获得的知识来确定骨关节炎药物干预或基因治疗模式的目标分子。这一培训将使我成为一名具有独特资格的临床科学家,以扩大基础研究和临床研究之间的相互作用。
英文摘要
A MCSDA would allow me as a veterinary surgeon and Ph.D., to expand my knowledge of cartilage biology and further understand chondrocyte metabolism in the search of preventive or treatment modalities for osteoarthritis. The mentor I have chosen is internationally recognized in intracellular signaling and has a well documented record of training scientists to become independent researchers. The studies outlined in this proposal examine the role of Rho-subfamily GTP-binding protein signaling in chondrocyte differentiation. Rho-binding proteins (Cdc42, Rac, RhoA) regulate actin cytoskeletal architecture and are involved in interleukin-1 (IL-1) signaling which induces chondrocyte dedifferentiation and cartilage degradation. Insulin-like growth factor-I (IGF-I) promotes the phenotypic expression of differentiated chondrocytes and can alleviate the degradative effects of IL-1 and tumor necrosis factor (TNF). Thus, the maintainance of a differentiated chondrocytes phenotype, and the key to prevention of osteoarthritis, may lie in IGF- I-regulated cytokine signaling through Cdc42, Rac, or RhoA. The broad objective of this study is to define the role IGF-I plays in the regulation of IL-1/TNF-induced dedifferentiation. During Phase I training, I will gain experience in biochemical and molecular-based approaches to study Rho-protein signaling pathways in chondrocytes. Aim 1 will examine how IGF-I, IL-1 and TNF influence the activation and localization of Cdc42, Rac, and RhoA. Aim 2 will employ microinjection methods to determine if mutated (constitutively active or inactive) Rho-proteins can prompt morphologic dedifferentiation. And Aim 3 will investigate the ability of vaccinia virus-expressed, mutated (constitutively active or inactive) Rho-proteins to incite phenotypic dedifferentiation. In Phase II, I will begin to develop an independent research program which will further extend my knowledge of Rho-proteins signaling in chondrocytes with emphasis on identifying Rho-target proteins involved in chondrocyte differentiation. I will focus on Rho kinase, a specific target for RhoA, and PAK-2 (p21-activated kinase), a specific target for Cdc42 and Rac. The vaccinia virus system will be used to express constitutively active or kinase-dead mutants of Rho kinase an PAK-2 to determine the effects of these kinases on chondrocyte differentiation. The expectation is that these studies will provide important insights into the regulation of chondrocyte differentiation while the ultimate goal is to use the knowledge gained to identify target molecules for the development of drug intervention or gene therapy modalities for osteoarthritis. This training would allow me to pursue an academic career as a clinician scientist with the unique qualifications to expand the interactions between basic and clinical research.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Mitoprotective therapy for treatment of ankle PTOA
-
批准号:9445145
-
项目类别:
-
资助金额:$39.14万
-
财政年份:2017
-
负责人:LISA A FORTIER
-
依托单位:
Mitoprotective therapy for treatment of ankle PTOA
-
批准号:9754782
-
项目类别:
-
资助金额:$55.88万
-
财政年份:2017
-
负责人:LISA A FORTIER
-
依托单位:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
-
批准号:8697945
-
项目类别:
-
资助金额:$101.24万
-
财政年份:2014
-
负责人:LISA A FORTIER
-
依托单位:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
-
批准号:9283228
-
项目类别:
-
资助金额:$94.78万
-
财政年份:2014
-
负责人:LISA A FORTIER
-
依托单位:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
-
批准号:8838048
-
项目类别:
-
资助金额:$98.24万
-
财政年份:2014
-
负责人:LISA A FORTIER
-
依托单位:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
-
批准号:9145633
-
项目类别:
-
资助金额:$94.46万
-
财政年份:2014
-
负责人:LISA A FORTIER
-
依托单位:
GTPase Activating Proteins in Aging and Osteoarthritis
-
批准号:7230219
-
项目类别:
-
资助金额:$15.86万
-
财政年份:2006
-
负责人:LISA A FORTIER
-
依托单位:
GTPase Activating Proteins in Aging and Osteoarthritis
-
批准号:7096245
-
项目类别:
-
资助金额:$19.73万
-
财政年份:2006
-
负责人:LISA A FORTIER
-
依托单位:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
-
批准号:6349717
-
项目类别:
-
资助金额:$10.28万
-
财政年份:2000
-
负责人:LISA A FORTIER
-
依托单位:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
-
批准号:6627909
-
项目类别:
-
资助金额:$12.18万
-
财政年份:2000
-
负责人:LISA A FORTIER
-
依托单位:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
-
批准号:6497165
-
项目类别:
-
资助金额:$11.52万
-
财政年份:2000
-
负责人:LISA A FORTIER
-
依托单位:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
-
批准号:6041145
-
项目类别:
-
资助金额:$9.12万
-
财政年份:2000
-
负责人:LISA A FORTIER
-
依托单位:
GROWTH FACTOR ENHANCED CARTILAGE RESURFACING
-
批准号:2633625
-
项目类别:
-
资助金额:$3.31万
-
财政年份:1998
-
负责人:LISA A FORTIER
-
依托单位:
GROWTH FACTOR ENHANCED CARTILAGE RESURFACING
-
批准号:2005975
-
项目类别:
-
资助金额:$3.12万
-
财政年份:1997
-
负责人:LISA A FORTIER
-
依托单位:
GROWTH FACTOR ENHANCED CARTILAGE RESURFACING
-
批准号:2078167
-
项目类别:
-
资助金额:$2.99万
-
财政年份:1996
-
负责人:LISA A FORTIER
-
依托单位:
海外基金